Trial Profile
Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Ifosfamide (Primary) ; Methotrexate (Primary) ; Nivolumab (Primary) ; Sunitinib (Primary)
- Indications Alveolar soft part sarcoma; Bone cancer; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ImmunoSarc
- 24 Oct 2023 Results (n=26; from Oct. 2019 to Apr. 2023) assessing the efficacy and safety of sunitinib and nivolumab in vascular sarcomas cohort, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Results (n=20 of phase Ib, cohort 7b) hypothesizing that the addition of an anti-PD1 (nivolumab) would increase the antitumor activity of commonly used upfront polychemotherapy in leiomyosarcoma of doxorubicin plus dacarbazine presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 24 Mar 2023 Planned End Date changed from 30 Sep 2022 to 30 Jun 2025.